001     166386
005     20240229133520.0
024 7 _ |a 10.1159/000508375
|2 doi
024 7 _ |a pmid:32365351
|2 pmid
024 7 _ |a 0028-3835
|2 ISSN
024 7 _ |a 1423-0194
|2 ISSN
024 7 _ |a altmetric:102578248
|2 altmetric
037 _ _ |a DKFZ-2020-02874
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Oleari, Roberto
|b 0
245 _ _ |a A novel SEMA3G mutation in two siblings affected by syndromic GnRH deficiency.
260 _ _ |a Basel
|c 2021
|b Karger
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1641806389_31476
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021;111(5):421-441
520 _ _ |a Gonadotropin-releasing hormone (GnRH) deficiency causes hypogonadotropic hypogonadism (HH), a rare genetic disorder that impairs sexual reproduction. HH can be due to defective GnRH-secreting neuron development or function and may be associated with other clinical signs in overlapping genetic syndromes. With most of the cases being idiopathic, genetics underlying HH is still largely unknown.To assess the contribution of mutated Semaphorin 3G (SEMA3G) gene in the onset of a syndromic form of HH, characterized by intellectual disabilities and facial dysmorphic features.By combining homozygosity mapping with exome sequencing, we identified a novel variant in SEMA3G gene. We then applied mouse as a model organism to examine SEMA3G expression and its functional requirement in vivo. Further, we applied homology modelling in silico and cell culture assays in vitro to validate the pathogenicity of the identified gene variant.We found that: SEMA3G is expressed along the migratory route of GnRH neurons and in the developing pituitary; SEMA3G affects GnRH neuron development, but is redundant in the adult hypothalamic-pituitary-gonadal axis; mutated SEMA3G alters binding properties in silico and in vitro to its PlexinAs receptors and attenuates its effect on the migration of immortalized GnRH neurons.In silico, in vitro and in vivo models revealed that SEMA3G regulates GnRH neuron migration and that its mutation affecting receptor selectivity may be responsible for the HH-related defects.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Andrè, Valentina
|b 1
700 1 _ |a Lettieri, Antonella
|b 2
700 1 _ |a Tahir, Sophia
|b 3
700 1 _ |a Roth, Lise
|b 4
700 1 _ |a Paganoni, Alyssa
|b 5
700 1 _ |a Eberini, Ivano
|b 6
700 1 _ |a Parravicini, Chiara
|b 7
700 1 _ |a Scagliotti, Valeria
|b 8
700 1 _ |a Cotellessa, Ludovica
|b 9
700 1 _ |a Bedogni, Francesco
|b 10
700 1 _ |a De Martini, Lisa Benedetta
|b 11
700 1 _ |a Corridori, Maria Vittoria
|b 12
700 1 _ |a Gulli, Simona
|b 13
700 1 _ |a Augustin, Hellmut G
|0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
|b 14
|u dkfz
700 1 _ |a Gaston-Massuet, Carles
|b 15
700 1 _ |a Hussain, Khalid
|b 16
700 1 _ |a Cariboni, Anna
|b 17
773 _ _ |a 10.1159/000508375
|0 PERI:(DE-600)1483028-0
|n 5
|p 421-441
|t Neuroendocrinology
|v 111
|y 2021
|x 1423-0194
909 C O |p VDB
|o oai:inrepo02.dkfz.de:166386
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Herz-Kreislauf-Stoffwechselerkrankungen
|1 G:(DE-HGF)POF3-320
|0 G:(DE-HGF)POF3-321
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Basic Concepts
|x 0
914 1 _ |y 2021
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2020-08-26
|w ger
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2020-08-26
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROENDOCRINOLOGY : 2018
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-08-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-08-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-08-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROENDOCRINOLOGY : 2018
|d 2020-08-26
920 1 _ |0 I:(DE-He78)A190-20160331
|k A190
|l A190 Vaskuläre Onkologie und Metastasierung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A190-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21